Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy

BMC Nephrol. 2020 Jul 9;21(1):260. doi: 10.1186/s12882-020-01911-9.

Abstract

Background: The seroprevalence of human Parvovirus B19 (PVB19) is 70-85% in adults worldwide. PVB19 is the etiologic agent of the fifth disease, is a cause of aplastic anemia, and can be associated with kidney injury. We aimed to describe the cases of 4 patients with kidney injury related to PVB19 primary infection, and to evaluate the seroprevalence of PVB19 and the incidence of PVB19 primary infection in patients undergoing a native kidney biopsy.

Methods: Cases of PVB19 infection with kidney injury were reviewed from the archives of the department of Nephrology. A systematic screening of anti-PVB19 IgG and IgM antibodies and viral DNA was performed in sera from 100 consecutive patients with a kidney biopsy in 2017-2018.

Results: The 4 patients with PVB19 infection-associated kidney disease displayed: one lupus-like glomerulonephritis (GN) without lupus auto-antibodies, one minimal change disease with tubular necrosis, one secondary hemolytic and uremic syndrome and one membrano-proliferative GN. In the 100 patients biopsied, 67 had elevated anti-PVB19 IgG, among whom 8 had elevated IgM, without circulating viral DNA, without any particular renal pathological pattern. One additional patient showed a seroconversion at the time of kidney biopsy, which revealed a class V lupus nephritis.

Conclusion: PVB19 primary infection can be associated with different kidney diseases. The seroprevalence of PVB19 among patients with a kidney biopsy is similar to the overall population, and primary infection is rarely documented (1%) after systematic screening. Whether PV19 is nephrotoxic, or triggers renal endothelial injury and immune activation, remains to be elucidated.

Keywords: Glomerulonephritis; Parvovirus B19; Prevalence; Primary infection; Thrombotic microangiopathy.

MeSH terms

  • Acute Kidney Injury / blood
  • Acute Kidney Injury / immunology
  • Acute Kidney Injury / pathology
  • Acute Kidney Injury / virology*
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Viral / immunology*
  • Biopsy
  • DNA, Viral / blood*
  • Erythema Infectiosum / blood
  • Erythema Infectiosum / complications
  • Erythema Infectiosum / immunology*
  • Female
  • Glomerulonephritis / blood
  • Glomerulonephritis / immunology
  • Glomerulonephritis / pathology
  • Glomerulonephritis / virology
  • Glomerulonephritis, Membranoproliferative / blood
  • Glomerulonephritis, Membranoproliferative / immunology
  • Glomerulonephritis, Membranoproliferative / pathology
  • Glomerulonephritis, Membranoproliferative / virology
  • Hemolytic-Uremic Syndrome / blood
  • Hemolytic-Uremic Syndrome / immunology
  • Hemolytic-Uremic Syndrome / pathology
  • Hemolytic-Uremic Syndrome / virology
  • Humans
  • Immunoglobulin G / immunology
  • Immunoglobulin M / immunology
  • Incidence
  • Kidney
  • Kidney Tubular Necrosis, Acute / blood
  • Kidney Tubular Necrosis, Acute / immunology
  • Kidney Tubular Necrosis, Acute / pathology
  • Kidney Tubular Necrosis, Acute / virology
  • Male
  • Middle Aged
  • Nephrosis, Lipoid / blood
  • Nephrosis, Lipoid / immunology
  • Nephrosis, Lipoid / pathology
  • Nephrosis, Lipoid / virology
  • Parvovirus B19, Human / genetics
  • Parvovirus B19, Human / immunology*
  • Seroepidemiologic Studies
  • Viremia / blood
  • Young Adult

Substances

  • Antibodies, Viral
  • DNA, Viral
  • Immunoglobulin G
  • Immunoglobulin M